- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Praluent® | REGN727 | SAR-236553 | SAR236553
alirocumab is an approved drug (EMA & FDA (2015))
Compound class: Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Based on peptide sequence matches we presume alirocumab is H1H316P in the patent document .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Abifadel M, Elbitar S, El Khoury P, Ghaleb Y, Chémaly M, Moussalli ML, Rabès JP, Varret M, Boileau C. (2014)
Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs.
Curr Atheroscler Rep, 16 (9): 439. [PMID:25052769]
2. Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA. (2014)
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
Am J Cardiol, 114 (5): 711-5. [PMID:25060413]
3. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. (2014)
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.
Int J Cardiol, 176 (1): 55-61. [PMID:25037695]
4. Sleeman MW, Martin JH, Huang TT, MacDonald D. (2011)
High affinity human antibodies to PCSK9.
Patent number: US8062640. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 15/12/2008. Publication date: 22/11/2011.